Quality standard
Quality statements
Statement 1 Adults with a new diagnosis of colorectal cancer have testing for Lynch syndrome. [new 2022]
Statement 2 Adults with early rectal cancer discuss the implications of all potential treatment options with their healthcare professional. [new 2022]
Statement 3 Adults with metastatic colorectal cancer suitable for systemic anti‑cancer treatment have testing to identify tumours with RAS and BRAF V600E mutations. [new 2022]
Statement 4 Adults who have had potentially curative surgical treatment for non‑metastatic colorectal cancer have follow-up for the first 3 years to detect local recurrence and distant metastases. [2012, updated 2022]
In 2022, this quality standard was updated and statements prioritised in 2012 were updated ([2012, updated 2022]) or replaced ([new 2022]). For more information, see update information.